Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Biogen Idec, Knopp Neurosciences to develop late-stage ALS drug candidate
October 2010
SHARING OPTIONS:

WESTON, Mass.Biogen Idec and Knopp Neurosciences recently announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole), a novel oral neuroprotective therapy, for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications. Under the terms of the agreement, Biogen Idec will lead the development of KNS-760704 for ALS and its potential commercialization in global markets, with Knopp providing development support and conducting certain U.S. commercialization activities. Biogen Idec will purchase $60 million of Knopp stock, provide an upfront payment of $20 million and additional payments of up to $265 million based on the achievement of development, regulatory and sales milestones. Biogen Idec will also pay tiered, double-digit royalties to Knopp on worldwide sales.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.